Alogliptin (Benzoate)

[1]Feng J, et, al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007 May 17;50 (10) :2297-300.|[2]Ta NN, et, al. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis. 2010 Dec;213 (2) :429-35.|[3]Hao FL, et, al. The neurovascular protective effect of alogliptin in murine MCAO model and brain endothelial cells. Biomed Pharmacother. 2019 Jan;109:181-187.|[4]Asakawa T, et, al. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. Life Sci. 2009 Jul 17;85 (3-4) :122-6.|[5]Moritoh Y, et al. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. Eur J Pharmacol. 2009 Jan 14;602 (2-3) :448-54.

Biochem Biophys Res Commun. 2019 Apr 2;511 (2) :387-393. |Biol Chem. 2023 Jan 12;404 (6) :633-643.|Chromatography. 2015,36 (1) :19-24.|Research Square Preprint. 2025 Jan 08.|Sci Rep. 2019 Dec 2;9 (1) :18094.|Sci Signal. 2023 Jan 17;16 (768) :eabh1083.